Active Ingredient History
Cytarabine is a pyrimidine nucleoside analog. Cytarabine or cytosine arabinoside (Cytosar-U or Depocyt) is a chemotherapy agent used mainly in the treatment of cancers of white blood cells such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma. It also has antiviral and immunosuppressant properties. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It is a cell cycle phase-specific, affecting cells only during the S phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA polymerase. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.The drug has a short plasma half-life, low stability and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus, various prodrug strategies and delivery systems have been explored extensively to enhance the half-life, stability and delivery of cytarabine. Alternative, delivery systems of cytarabine have emerged for the treatment of different cancers. The liposomal-cytarabine formulation has been approved for the treatment of lymphomatous meningitis. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acne Vulgaris (Phase 2)
Allergy and Immunology (Phase 1)
Anemia (Phase 2)
Anemia, Aplastic (Phase 2)
Anemia, Refractory (Phase 3)
Antigens, CD19 (Phase 2)
Antigens, CD20 (Phase 1)
Astrocytoma (Phase 1/Phase 2)
Autoimmune Diseases (Phase 2)
Biomarkers (Phase 2)
Bone Marrow Cells (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Burkitt Lymphoma (Phase 4)
Cardiotoxicity (Phase 3)
Cerebellar Diseases (Phase 2)
Cerebrospinal Fluid (Phase 1)
Chromosome Aberrations (Phase 2)
Clonal Hematopoiesis (Phase 2)
Cognition Disorders (Phase 2)
Core Binding Factors (Phase 4)
Diabetes Mellitus, Type 2 (Phase 1)
Diploidy (Phase 2)
Down Syndrome (Phase 3)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 2/Phase 3)
Encephalitis (Phase 2)
Ependymoma (Phase 2)
Fusion Proteins, bcr-abl (Phase 2)
Geriatrics (Phase 3)
Glioblastoma (Phase 1/Phase 2)
Glioma (Phase 1/Phase 2)
Graft vs Host Disease (Phase 3)
Hematologic Neoplasms (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 3)
Histiocytosis, Langerhans-Cell (Phase 3)
HIV (Phase 2)
HIV Infections (Phase 3)
Hodgkin Disease (Phase 3)
Induction Chemotherapy (Phase 3)
Intestinal Neoplasms (Phase 2)
Isocitrate Dehydrogenase (Phase 3)
Lambert-Eaton Myasthenic Syndrome (Phase 2)
Leukemia (Phase 4)
Leukemia, B-Cell (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Eosinophilic, Acute (Phase 3)
Leukemia, Erythroblastic, Acute (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)
Leukemia, Lymphoid (Phase 4)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Megakaryoblastic, Acute (Phase 1)
Leukemia, Monocytic, Acute (Phase 3)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Accelerated Phase (Phase 1)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Acute (Phase 3)
Leukemia, Myelomonocytic, Chronic (Phase 3)
Leukemia, Myelomonocytic, Juvenile (Phase 2)
Leukemia, Neutrophilic, Chronic (Phase 1)
Leukemia, Plasma Cell (Phase 2)
Leukemia, Prolymphocytic (Phase 1/Phase 2)
Leukemia, Prolymphocytic, B-Cell (Phase 2)
Leukemia, Prolymphocytic, T-Cell (Phase 2)
Leukemia, Promyelocytic, Acute (Phase 4)
Leukemia, T-Cell (Phase 2/Phase 3)
Lung Diseases (Phase 3)
Lupus Erythematosus, Systemic (Phase 2)
Lymphohistiocytosis, Hemophagocytic (Phase 2)
Lymphoma (Phase 4)
Lymphoma, AIDS-Related (Phase 2)
Lymphoma, B-Cell (Phase 3)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 4)
Lymphoma, Large-Cell, Immunoblastic (Phase 4)
Lymphoma, Mantle-Cell (Phase 4)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 3)
Lymphoproliferative Disorders (Phase 2)
Mediastinal Neoplasms (Phase 4)
Medulloblastoma (Phase 2)
Melanoma (Phase 3)
Meningeal Neoplasms (Phase 4)
Meningitis (Phase 2)
Mucositis (Phase 3)
Multiple Myeloma (Phase 3)
Multiple Sclerosis (Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Mutation (Phase 2)
Myasthenia Gravis (Phase 2)
Myelodysplastic Syndromes (Phase 4)
Myeloproliferative Disorders (Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasm, Residual (Phase 2)
Neoplasms ()
Neuroblastoma (Phase 1/Phase 2)
Neuromyelitis Optica (Phase 2)
Neutropenia (Phase 3)
Opsoclonus-Myoclonus Syndrome (Phase 2)
Organ Transplantation (Phase 2)
Pediatrics (Phase 1)
Peripheral Blood Stem Cell Transplantation (Phase 1/Phase 2)
Plasmablastic Lymphoma (Phase 1/Phase 2)
Plasmacytoma (Phase 2)
Polycythemia Vera (Phase 1/Phase 2)
Primary Myelofibrosis (Phase 2)
Prognosis (Phase 2)
Prostatic Neoplasms (Phase 2)
Recurrence (Phase 3)
Renal Insufficiency, Chronic (Phase 3)
Rhabdoid Tumor (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Myeloid (Phase 3)
Stents (Phase 2)
Stiff-Person Syndrome (Phase 2)
Testicular Neoplasms (Phase 3)
Thrombocythemia, Essential (Phase 1/Phase 2)
Thrombocytopenia (Phase 2)
Translocation, Genetic (Phase 2)
Vascular Grafting (Phase 3)
Vasculitis, Central Nervous System (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
